

Federico Rotolo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9497291/publications.pdf>

Version: 2024-02-01

25
papers

751
citations

840776

11
h-index

580821

25
g-index

30
all docs

30
docs citations

30
times ranked

1608
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumor Mutation Burden as a Biomarker in Resected Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 2995-3006.	1.6	223
2	IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial. <i>Lancet Oncology</i> , 2019, 20, 1160-1170.	10.7	119
3	Empirical extensions of the lasso penalty to reduce the false discovery rate in high-dimensional Cox regression models. <i>Statistics in Medicine</i> , 2016, 35, 2561-2573.	1.6	74
4	<code>parfm</code> : Parametric Frailty Models in R. <i>Journal of Statistical Software</i> , 2012, 51, .	3.7	48
5	Surrogate End Points for Overall Survival in Loco-Regionally Advanced Nasopharyngeal Carcinoma: An Individual Patient Data Meta-analysis. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	6.3	37
6	Statistical controversies in clinical research: prognostic gene signatures are not (yet) useful in clinical practice. <i>Annals of Oncology</i> , 2016, 27, 2160-2167.	1.2	33
7	<code>surrosv</code> : An R package for the evaluation of failure time surrogate endpoints in individual patient data meta-analyses of randomized clinical trials. <i>Computer Methods and Programs in Biomedicine</i> , 2018, 155, 189-198.	4.7	29
8	Bias and precision of methods for estimating the difference in restricted mean survival time from an individual patient data meta-analysis. <i>BMC Medical Research Methodology</i> , 2016, 16, 37.	3.1	28
9	Adjuvant cisplatin-based chemotherapy in nonsmall-cell lung cancer: new insights into the effect on failure type via a multistate approach. <i>Annals of Oncology</i> , 2014, 25, 2162-2166.	1.2	26
10	Identification of biomarker-by-treatment interactions in randomized clinical trials with survival outcomes and high-dimensional spaces. <i>Biometrical Journal</i> , 2017, 59, 685-701.	1.0	26
11	<code>biospear</code> : an R package for biomarker selection in penalized Cox regression. <i>Bioinformatics</i> , 2018, 34, 112-113.	4.1	16
12	A simulation procedure based on copulas to generate clustered multi-state survival data. <i>Computer Methods and Programs in Biomedicine</i> , 2013, 109, 305-312.	4.7	13
13	A Poisson approach to the validation of failure time surrogate endpoints in individual patient data meta-analyses. <i>Statistical Methods in Medical Research</i> , 2019, 28, 170-183.	1.5	12
14	Genome-wide copy number analyses of samples from LACE-Bio project identify novel prognostic and predictive markers in early stage non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2018, 7, 416-427.	2.8	11
15	Predictive classifier for intensive treatment of head and neck cancer. <i>Cancer</i> , 2020, 126, 5263-5273.	4.1	11
16	Accounting for grouped predictor variables or pathways in high-dimensional penalized Cox regression models. <i>BMC Bioinformatics</i> , 2020, 21, 277.	2.6	11
17	Robust estimation of the expected survival probabilities from high-dimensional Cox models with biomarker-by-treatment interactions in randomized clinical trials. <i>BMC Medical Research Methodology</i> , 2017, 17, 83.	3.1	10
18	Evaluation of Treatment Effect with Paired Failure Times in a Single-Arm Phase II Trial in Oncology. <i>Computational and Mathematical Methods in Medicine</i> , 2018, 2018, 1-8.	1.3	8

#	ARTICLE	IF	CITATIONS
19	Testing the treatment effect on competing causes of death in oncology clinical trials. BMC Medical Research Methodology, 2014, 14, 72.	3.1	7
20	First-line treatment in metastatic colorectal cancer: Important or crucial?. European Journal of Cancer, 2017, 84, 363-366.	2.8	4
21	Incorporation of nested frailties into semiparametric multi-state models. Statistics in Medicine, 2016, 35, 609-621.	1.6	1
22	Predictor of effectiveness of treatment intensification on overall survival in head and neck cancer (HNC). Annals of Oncology, 2018, 29, viii375-viii376.	1.2	1
23	An alternative trial-level measure for evaluating failure-time surrogate endpoints based on prediction error. Contemporary Clinical Trials Communications, 2019, 15, 100402.	1.1	1
24	Prediction of treatment benefit in high-dimensional cox models via gene signatures in randomized clinical trials. Trials, 2015, 16, .	1.6	0
25	Development and Validation of Genomic Signatures. , 2018, , .		0